Prothrombotic factors, including factor V leiden mutations (19%), antiphospholipid antibodies (16%), and protein C deficiency (15%) were identified in those JAK2 V617F positive patients, but prevalence of OCP use was unknown [22]. This evidence concerns the gene JAK2 and hyperinsulinemic hypoglycemia, familial, 4.